Merck & Co Inc

NYSE: MRK
$98.05
-$1.47 (-1.5%)
Closing Price on December 20, 2024

MRK Articles

The Dow is set to close with a modest gain Friday led by Verizon, Merck, UnitedHealth, and Johnson & Johnson.
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
DowDuPont, General Electric, Exxon Mobil, and Merck led the Dow to a solid gain Wednesday.
Pfizer, Merck, McDonald's, and Coca-Cola were the big losers Tuesday among the 30 Dow stocks.
Merck released better-than-expected quarterly results and full-year guidance before the markets opened on Tuesday.
Both Pfizer and Merck are scheduled to release their most recent quarterly results before the markets open on Tuesday. These are the two biggest companies in the pharma industry and they can set the...
24/7 Wall St. has put together a preview of Apple, McDonald's, Pfizer and other Dow companies scheduled to report their quarterly results this week.
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The top analyst upgrades, downgrades and other research calls from Monday include Amazon.com, Caterpillar, Exxon Mobil, Honeywell, Lululemon Athletica, Merck, Petrobras and Under Armour.
The top analyst upgrades, downgrades and other research calls from Tuesday include Bristol-Myers Squibb, Chesapeake Energy, Coca-Cola, Dropbox, GrubHub, Merck, National Oilwell Varco, Netflix and...
Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates.
UnitedHealth, Merck, Verizon, and Caterpillar led the Dow to a nice gain Monday.
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Merck, Intel, JPMorgan Chase, and IBM led the Dow to a gain on Monday.
Shares of Merck had a boost early Monday after the firm announced that its Phase 3 trial of Keytruda for the treatment of metastatic non-small cell lung cancer met its primary endpoint.